Mergers & Acquisitions ·
Drugs Made In America agrees to merge with Power Analytics Global for $2.85B valuation
DMAADrugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. entered into an Amended and Restated Definitive Merger Agreement with Power Analytics Global Corp., fixing the transaction's closing valuation at $2,850,000,000. The deal structures a domestication of the SPAC to Delaware followed by a merger where PAGC survives as a wholly-owned subsidiary. Consideration consists of up to 265,116,279 new shares based on a reference price of at least $10.75. A key condition is PAGC's prior acquisition of APQC Inc., including its UltraSolar intellectual property. The transaction requires shareholder approval and the delivery of a fairness opinion from Newbridge Securities Corporation. Drugs Made In America Acquisition Corp. operates as a blank check company seeking to combine with a target in the artificial intelligence, advanced analytics, and quantum-resistant security solutions industry.